Menu
Your Cart

Magnetic Nanoparticles

Magnetic Nanoparticles
Apostle MiniEnrich for Enrichment of Short DNA fragments for NIPT and Oncology ApplicationsPrecise DNA sizing can boost sequencing efficiency, reduce cost, improve data quality, and even allow sequencing of low-input samples, while current pervasive DNA sizing approaches are incap- able of different..
$270.00
Apostle MiniEnrich for Enrichment of Short DNA fragments for NIPT and Oncology ApplicationsPrecise DNA sizing can boost sequencing efficiency, reduce cost, improve data quality, and even allow sequencing of low-input samples, while current pervasive DNA sizing approaches are incap- able of different..
$672.50
Apostle MiniMax technology ensures precise capture and separation of DNA, RNA, and other biomolecules. This is achieved through Apostle’s novel proprietary MiniMax magnetic nanoparticles with innovative features:Novel material composition and surface chemistry - completely distinct from the conventi..
$864.00
Apostle MiniMax technology ensures precise capture and separation of DNA, RNA, and other biomolecules. This is achieved through Apostle’s novel proprietary MiniMax magnetic nanoparticles with innovative features:Novel material composition and surface chemistry - completely distinct from the conventi..
$3,434.40
Next-generation purification, size selection, and long-read size selection.The Apostle MiniEnrich Size Selection Beads is designed for size selection of DNA fragments from a mixture of DNA with various sizes, which potentially benefits downstream assays like NGS and other molecular biology workflows..
$415.04
Next-generation purification, size selection, and long-read size selection.The Apostle MiniEnrich Purification Beads is designed for purification and clean-up of DNA fragments from the contaminants in NGS and molecular biology workflows. It can be used on samples after DNA isolation, fragmentation, ..
$415.04
Showing 1 to 6 of 6 (1 Pages)
Nature Communications just published a clinical study, including 2125 cancer patients, 9 cancer types, using the Apostle Minimax cfDNA technology. This study demonstrates the ability of its model to detect early-stage cancers using cfDNA, including those of pancreatic origin, with high sensitivity that is comparable to that of late-stage detection. Congratulations to this clinical research team. To date, the Apostle Minimax cfDNA technology has been used in 2 articles published in Nature Medicine, 1 in Nature Communications, 1 in Science Translational Medicine, 1 in PNAS, and over 50 scientific articles in different journals.